<i>ESR1</i> Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.

Authors : Turner NC, Swift C, Kilburn L, Fribbens C, Beaney M, Garcia-Murillas I, Budzar AU, Robertson JFR, Gradishar W, Piccart-Gebhart M, Schiavon G, Bliss JM, Dowsett M, Johnston SRD, Chia SK
Year : 2020
Journal : Clin Cancer Res
Volume : 26
Pages : 5172-5177